Assignment of the Human Mitochondrial NAD+-Specific Isocitrate Dehydrogenase α Subunit (IDH3A) Gene to 15q25.1 → q25.2 byin SituHybridization

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

“…Recent findings suggest that the IDH2 may be the main catalyst for the oxidation of isocitrate to α-ketoglutarate in the citric acid cycle [6]. IDH3 is composed of three subunits encoded by IDH3A (subunit alpha), on 15q25.1-q25.2 [7], by IDH3B (subunit beta) on 20p13 [10] and by IDH3G (subunit gamma), on Xq28. IDH3 is a multi-tetrameric enzyme (2α1β1γ) with α−subunits being catalytic and the β-and γ -subunits being believed to be regulatory [15,19].…”

Assignment<footref rid="foot01">¹</footref> of mitochondrial NAD⁺-specific isocitrate dehydrogenase β subunit gene (IDH3B) to human chromosome band 20p13 by in situ hybridization and radiation hybrid mapping

“…Among the three kinds of ICDH isoforms that exist in yeast and mammalian systems, mitochondrial NAD + -specific isocitrate dehydrogenase (IDH3) has been thought to play a major role in the oxidative decarboxylation of isocitrate in the TCA cycle since its activity is regulated by numerous allosteric regulators (Plaut and Gabriel, 1983). To study the possible roles of IDH in the genetic diseases caused by defects in energy metabolism and mitochondrial biogenesis (Elzinga et al, 1993), we have previously mapped the human IDH3 · subunit gene (IDH3A) (Kim et al, 1995;Huh et al, 1996). Here, we report assignment of the human IDH3 ß subunit gene (IDH3B) to human chromosome 20p13 by fluorescence in situ hybridization and radiation hybrid mapping.…”

Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma

“…IDH2 is a mitochondrial enzyme that catalyzes a similar reaction with IDH1. IDH3 is a mitochondrial enzyme that catalyzes irreversible oxidative decarboxylation of isocitrate through an NAD + dependent manner ( 6 , 7 ). Several pioneering studies revealed that missense mutations in IDH1/2 are frequently identified in several types of human malignancies, including lower grade glioma, acute myeloid leukemia, cholangiocarcinoma, and chondrosarcoma ( 8 – 11 ).…”